MYMDライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:50):

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease...

Stats
本日の出来高	38 112.00
平均出来高	227 162
時価総額	6.40M
EPS	$0 ( 2024-03-29 )
次の収益日	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.560
ATR14	$0.0280 (0.94%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-24	Rivard Paul	Buy	150 000	Common stock
2023-08-17	Rivard Paul	Buy	25 000	Common stock
2023-06-07	Chapman Christopher C Jr	Buy	300 000	Employee Stock Option (Right to Buy)
2023-06-07	Kaplin Adam	Buy	150 000	Employee Stock Option (Right to Buy)
2023-06-07	Uzonwanne Jude	Buy	150 000	Employee Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 84 transactions
Buy: 8 636 568 \| Sell: 532 775

ボリューム相関

長: 0.21 (neutral)

短: 0.32 (neutral)

Signal:(54.482) Neutral

MyMD Pharmaceuticals, 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

MyMD Pharmaceuticals, 相関 - 通貨/商品

0.82
( strong )

0.79
( moderate )

0.00
( neutral )

0.80
( moderate )

-0.73
( moderate negative )

-0.83
( strong negative )

MyMD Pharmaceuticals, 財務諸表

Annual	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-2.59

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-2.59

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-11.68

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.850

Financial Reports:

No articles found.

MyMD Pharmaceuticals,

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.